Lb Pharmaceuticals INC S-1 registration statements

LB Pharmaceuticals has filed a registration statement for the resale of up to 4,778,491 shares of common stock by existing selling stockholders.

LB Pharmaceuticals Inc. filed an S-1MEF to register an additional $21.1 million in common stock for its public offering, bringing the total offering to approximately $327.8 million, though auditors noted a going concern.

LB Pharmaceuticals Inc. is launching an initial public offering of 16,666,667 shares to raise capital for the clinical development of its lead candidate, LB-102, for schizophrenia and bipolar depression.

LB Pharmaceuticals Inc. is launching its initial public offering to fund the development of LB-102, a Phase 3-ready drug for schizophrenia and bipolar depression, following positive Phase 2 results.